Trends and variations in intravenous vitamin D use among hemodialysis patients in the United States

Renal Failure

Volumn 35, Issue 1, 2013, Pages 1-8

  Beaubrun, Anne C ^a   Brookhart, M Alan ^b   Sleath, Betsy ^a   Wang, Lily ^c   Kshirsagar, Abhijit V ^d  

^a University of North Carolina   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Hemodialysis; Patterns; Trends; Variations; Vitamin D

Indexed keywords

CALCITRIOL; DOXERCALCIFEROL; PARICALCITOL;

ADULT; AGE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; TREND STUDY; UNITED STATES;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; VITAMIN D; VITAMINS;

EID: 84872470757     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.734260     Document Type: Article

References (18)

1. Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci. 2007;333(4):201-207. (Pubitemid 46624808)
2. Dennis VC, Albertson GL.Doxercalciferol treatment of secondary hyperparathyroidism. Ann PharM.A.cother. 2006;40(11):1955-1965. (Pubitemid 44747465)
3. M.A.rtin KJ, González EA. Vitamin D analogues for the M.A.nagement of secondary hyperparathyroidism. Am J Kidney Dis. 2001;38(5):S34-S40. (Pubitemid 33022203)
4. Dobrez DG, M.A.thes A, Amdahl M, M.A.rx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19(5):1174-1181. (Pubitemid 38628138)
5. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446-456. (Pubitemid 36910023)
6. Tentori F, Albert JM, Young EW, et al. The survival advantage for hemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2009;24(3):963-972.
7. DOPPS. DOPPS practice monitor. Available at: http://www. dopps.org/DPM/. Accessed M.A.y 10, 2012.
8. St. Peter W, Li S, Liu J, Gilbertson D, Arneson T, Collins A. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. PharM.A.cotherapy. 2009;29(2):154-164.
9. M.A.ssengill D. Tips and tricks III: more unique SAS/GRAPH® M.A.ps. SAS Institute. Available at: http://support.sas.com/rnd/papers/sugi30/sasM.A. pping3.pdf. Accessed October 5, 2011.
10. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70(10):1858- 1865. (Pubitemid 44684819)
11. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(9):1529-1539.
12. Palmer SC, McGregor DO, M.A.caskill P, Craig JC, Elder GJ, Strippoli GF. Meta-Analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147(12):840-853. (Pubitemid 351664426)
13. Ginde AA, Liu MC, CaM.A.rgo CA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169(6):626-632.
14. Owda A, Elhwairis H, Narra S, Towery H, OsaM.A. S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003;25(4):595-602. (Pubitemid 36944739)
15. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a M.A.jor determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol. 2000;11(2):330-334. (Pubitemid 30064856)
16. Kalantar-Zadeh K, Miller JE, Kovesdy CP, et al. Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D and survival in hemodialysis patients. J Bone Miner Res. 2010;25(12):2724-2734.
17. U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.
18. St. Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis. 2005;46(4):650-660. (Pubitemid 41383943)